Raymond James Financial Services Advisors Inc. Sells 42,899 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Raymond James Financial Services Advisors Inc. lowered its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVAGet Rating) by 29.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 100,394 shares of the company’s stock after selling 42,899 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Teva Pharmaceutical Industries were worth $810,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Private Trust Co. NA bought a new stake in Teva Pharmaceutical Industries during the 2nd quarter worth about $32,000. Credit Agricole S A bought a new stake in Teva Pharmaceutical Industries during the 2nd quarter worth about $34,000. Newbridge Financial Services Group Inc. grew its holdings in Teva Pharmaceutical Industries by 555.6% during the 3rd quarter. Newbridge Financial Services Group Inc. now owns 5,900 shares of the company’s stock worth $48,000 after acquiring an additional 5,000 shares during the last quarter. Ritholtz Wealth Management bought a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth about $85,000. Finally, Quantbot Technologies LP bought a new stake in Teva Pharmaceutical Industries during the 1st quarter worth about $110,000. Institutional investors own 50.39% of the company’s stock.

Teva Pharmaceutical Industries Stock Down 1.3 %

Teva Pharmaceutical Industries stock opened at $10.41 on Monday. The company’s 50 day simple moving average is $9.38 and its 200 day simple moving average is $9.00. Teva Pharmaceutical Industries Limited has a fifty-two week low of $6.78 and a fifty-two week high of $11.44. The firm has a market capitalization of $11.56 billion, a price-to-earnings ratio of -8.97 and a beta of 1.20. The company has a debt-to-equity ratio of 1.94, a current ratio of 0.99 and a quick ratio of 0.66.

Teva Pharmaceutical Industries (NYSE:TEVAGet Rating) last released its quarterly earnings data on Thursday, November 3rd. The company reported $0.56 earnings per share for the quarter, missing the consensus estimate of $0.58 by ($0.02). The firm had revenue of $3.60 billion for the quarter, compared to the consensus estimate of $3.86 billion. Teva Pharmaceutical Industries had a positive return on equity of 26.97% and a negative net margin of 8.52%. As a group, sell-side analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.4 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. BMO Capital Markets decreased their price objective on shares of Teva Pharmaceutical Industries from $11.00 to $10.00 and set a “market perform” rating on the stock in a report on Monday, November 7th. UBS Group lowered shares of Teva Pharmaceutical Industries from a “neutral” rating to a “sell” rating in a research note on Friday, November 4th. Jefferies Financial Group lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating and raised their target price for the company from $10.00 to $12.00 in a research note on Thursday. StockNews.com initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 12th. They issued a “buy” rating on the stock. Finally, JPMorgan Chase & Co. lowered shares of Teva Pharmaceutical Industries from a “neutral” rating to an “underweight” rating and reduced their target price for the company from $11.00 to $10.00 in a research note on Monday, November 14th. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $10.67.

Teva Pharmaceutical Industries Profile

(Get Rating)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.

Further Reading

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVAGet Rating).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.